Skip to content

Evaluating the Effect of Injectable Platelet-rich Fibrin on Accelerating Orthodontic Tooth Movement

Evaluating the Effect of Injectable Platelet-rich Fibrin on Accelerating Orthodontic Tooth Movement During Leveling and Alignment Stage Study Description

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06302296
Enrollment
14
Registered
2024-03-08
Start date
2026-12-20
Completion date
2027-07-15
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injectable Platelet-rich Fibrin, Tooth Mobility

Brief summary

One of the main goals of orthodontic treatment is the reduction of treatment time through faster tooth movement. The previous studies evaluating platelet-rich fibrin (PRF) and orthodontic tooth movement (OTM) are limited, which makes the results difficult to generalize.

Detailed description

One of the main goals of orthodontic treatment is the reduction of treatment time through faster tooth movement. The previous studies evaluating platelet-rich fibrin (PRF) and orthodontic tooth movement (OTM) are limited, which makes the results difficult to generalize. To this end, we set up this Randomized experiment to evaluate the effect of the injectable form of PRF (i-PRF) on OTM, using nonadditive containing i-PRF, which has higher levels of regenerative cells and growth factors compared with other PRF types because of the use of low centrifugation spee. Accordingly, we aimed to evaluate the effect of i-PRF on the rate of maxillary incisors leveling during comprehensive orthodontic treatment.

Interventions

DEVICEinjectable form of PRF

A group of patients in which participants will be undergo to orthodontic treatment will be received a 0.9 ml injection of PRF after 1st premolar extraction.

BEHAVIORALPlacebo injection

A group of patients in which participants will be undergo to traditional orthodontic treatment will be received a Placebo injection after 1st premolar extraction.

Sponsors

Hama University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 26 Years
Healthy volunteers
No

Inclusion criteria

* The patient's age (18-26). Severe or very severe irregularity of the upper incisors greater than (7 mm) according to Little's index, so it is recommended to extract the upper first premolar. * Class I or Class II malocclusion, first model according to Angle, with skeletal class I or II and a normal or mild vertical growth pattern. * All permanent upper teeth, up to the first molar, are present, with the possibility of attaching brackets to all teeth in a correct position. * The patient has good oral health.

Exclusion criteria

* • The presence of any systemic disease that affects orthodontic dental movement. * Severe malalignment of one of the teeth (palatal quadrant, ectopic canine, ectopic premolar). * The patient has undergone previous orthodontic treatment. * The patient is subject to any drug treatment that may affect orthodontic dental movement (cortisone, non-steroidal anti-inflammatory drugs). * The patient has poor oral health. * Commitment to periodic follow-up appointments.

Design outcomes

Primary

MeasureTime frameDescription
Leveling and alignment maxillary incisorsOne month ,two month,six month\- Alginate impressions were taken at insertion of the first archwire (0.014-in nickel-titanium) maxillary incisors Leveling and alignment. Leveling and alignment were achieved through the following sequence of archwires: 0.014-in nickel-titanium (NiTi), 0.016 × 0.022-in NiTi, 0.017 × 0.025-in NiTi, 0.019 × 0.025-in stainless steel (SS)(3).

Countries

Syria

Contacts

CONTACTFADI JNAID, Associate Professor
Drfadijnaid@gmail.com988499015
PRINCIPAL_INVESTIGATOREisa Salami, MSc student

Hama University

STUDY_CHAIRRabab Alsabbagh, Professor

Hama University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026